🔗 Share this article

While the United States undertakes sweeping adjustments to its immunization guidelines, an unexpected name has surfaced unexpectedly: Dr. Tracy Beth Høeg, a Danish American sports physician and epidemiologist who rose to prominence by casting doubt on COVID-19 shots during the pandemic and has concentrated on potential deaths following Covid vaccination in her recent time at the US Food and Drug Administration (FDA).

Proposed Overhauls to Pediatric Vaccine Schedule

Agency leaders had intended to unveil radical revisions to the childhood vaccination calendar recently, bringing the US with Denmark’s vaccine program, according to reports – a substantial departure that would place the US at odds with much of the global community with insufficient data for benefit. The planned update has been postponed until the new year.

Rather than Vinay Prasad, Dr. Høeg is set to present at the event. She was just designated temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to run the office this calendar year.

Consolidating Power at the Agency

Høeg's temporary position may indicate a tighter collaboration between the pharmaceutical and vaccine centers as Høeg and Prasad solidify control at the agency – and it points to a renewed priority upon reevaluating long-standing immunizations at the FDA.

Dr. Høeg has frequently advocated for discontinuing specific childhood vaccine recommendations in the US to become more similar to Denmark's approach, a country with nationalized medicine and a number of inhabitants roughly the size of the state of Wisconsin.

In her initial comments, she has continued to focus on immunizations – traditionally the purview of Dr. Prasad, chief of the FDA’s vaccine center – rather than drug regulation.

Concerns Over Background

Dr. Høeg has no obvious track record in drug development, regulation or management, which has been typical for past heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the FDA chief and CBER since earlier this year.

“She doesn’t seem to have any of the qualifications” for leading the CDER, said Jonathan Howard. “She’s never run a clinical trial. She lacks experience in leading a sizeable institution. She is not an expert in industry regulation.”

Previous commissioners of the center would “grasp laws and regulations and the research of pharmaceutical innovation”, said a former acting FDA commissioner. “Objectively, she has not acquired the type of experience that prior appointees who headed CBER have had.”

The drug center has an immense range of responsibilities at the FDA, she pointed out.

“The public just focuses on the new drug program, but the generic program approves numerous generic medications. There’s a biosimilars program, non-prescription drug unit and so forth, and every single one need to be managed,” Woodcock said. “The responsibility you overlook, that is precisely what that I always told people is going to bite you.”

Additionally, a major leadership component to the role, which supervises more than 5,000 personnel. “It is a massive administrative position, if you execute it properly,” she added.

Official Statement and Contentious Initiatives

Regarding concerns about Dr. Høeg's fitness for the role and whether this selection signifies increased cooperation among regulatory chiefs on vaccines, a representative said that the “concerns are based on incorrect premises”.

“This background matches the duties of her position,” the official stated, citing the period Dr. Høeg spent counseling the agency head on “pharmaceutical safety and oversight research, including predictive safety algorithms and immunization monitoring”.

As the temporary head, Dr. Høeg assumes responsibility for the commissioner’s controversial expedited review system, a controversial expedited therapy clearance system that allegedly troubled her predecessors. “How are these drugs being picked for this expedited pathway? Who makes the choices?” Dr. Howard asked. “There’s a lot of confidentiality occurring at the regulatory body right now.”

In general, he stated, “the agency looks to be trending towards less stringent rules of all drugs, except for shots.”

Public History on Vaccines

Concerning immunizations, Høeg has a more established, if concerning, track record, critics observe. She released a analysis using unconfirmed public submissions to assess the incidence of heart inflammation after COVID-19 immunization. She counseled the Florida surgeon general Joseph Ladapo, who reportedly have changed statistics to suggest COVID-19 vaccines are riskier than they are.

Among her “wish list” for the incoming federal leadership included altering regulations for novel immunizations and ending “unnecessary” vaccines, she remarked post-election on a audio program. At the agency, Høeg has reportedly suggested excluding teenage boys from obtaining COVID-19 vaccines.

“She’s an thorough true believer who commences with her conclusions and works backwards to retrofit the data in a very disingenuous, dishonest fashion,” Dr. Howard said.

Consolidating Power and a “Revenge Tour”

Høeg joined fellow skeptics, {like|